Amgen Inc (NASDAQ: AMGN) started Wednesday with an impressive 7.81% price surge, reaching $319.86 before closing at $296.70. Over the past year, AMGN has traded within a 52-week range of $253.30 to $335.88, reflecting moderate volatility within the Healthcare sector.
Despite a challenging five-year period marked by a -10.10% decline in both annual sales and earnings per share (EPS), Amgen’s current fiscal year shows improvement, with EPS rising 6.89%. The company’s market capitalization stands at $172.20 billion, supported by 538 million shares outstanding and a float of 537.25 million. As of the latest data, AMGN’s 50-day moving average is $288.69, while the 200-day moving average is $291.79.
AMGEN Inc (AMGN) Ownership Facts and Figures
Institutional investors remain highly active in Amgen’s stock, holding 82.34% ownership, compared to just 0.19% by insiders. On August 20, 2025, the company’s SVP & CCO sold 1,267 shares at $296.99 each, totaling $376,280, leaving them with 7,209 shares.
AMGEN Inc (AMGN) Earnings and Revenue Records
Wall Street analysts project Amgen’s earnings to reach $4.99 per share for the current fiscal year, with EPS forecasted to rise to 21.67 next year. Over the next five years, analysts expect EPS growth of 4.21%, a positive shift from the -10.10% decline seen in the previous five-year period.
AMGEN Inc (NASDAQ: AMGN) Trading Performance Indicators
Amgen’s liquidity remains solid, with a Quick Ratio of 0.99. The company’s Price-to-Earnings (P/E) ratio stands at 24.73, while its Beta score of 0.46 suggests lower volatility relative to the market. Amgen’s trailing twelve-month Price-to-Sales ratio is 4.80, and its Price-to-Free-Cash-Flow ratio is 16.24.
The company’s diluted EPS over the trailing twelve months is 12.93, projected to reach 4.85 in the next quarter and 21.67 within a year.
Technical Analysis of AMGEN Inc (AMGN)
Amgen’s trading activity has shown a positive trend, with a five-day average volume of 3.28 million—an increase from its year-to-date average of 2.74 million. Over the last nine days, its Stochastic %D was recorded at 71.34%, with an Average True Range (ATR) of 80.86, signaling heightened price movement.
The 100-day raw Stochastic average of 94.34% indicates strong upward momentum, compared to 91.08% over the last two weeks. In terms of volatility, Amgen’s 14-day historical volatility was 6.95, slightly above the 6.50 level recorded over the past 100 days.
In summary, AMGEN Inc (NASDAQ: AMGN) continues to demonstrate resilience and steady investor confidence, supported by improving earnings, strong institutional backing, and technical indicators that suggest potential for continued growth in the near term.